Skip to main content

Dandekar Atul's Form 4 filing

Maze Therapeutics, Inc. (MAZE) · filed Dec 31, 2025

Accession no.
0002050167-25-000007
Filed
Dec 31, 2025
Trade date
Dec 29-30, 2025
Filing delay
2 days
Rule 10b5-1 plan
Checked

This filing lists 5 non-derivative transactions and 2 derivative transactions. Open-market sales total $2.94M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Dandekar AtulCIK 0002050167Officer (CSBO)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Dec 29, 2025Common StockMOption exerciseAcquired+72,400$10.42+$754,40882,903Direct
Dec 29, 2025Common StockSSaleDisposed−66,365$40.51−$2,688,446.1516,538Direct
Dec 29, 2025Common StockSSaleDisposed−6,035$41.13−$248,219.5510,503Direct
Dec 30, 2025Common StockMOption exerciseAcquired+100$10.42+$1,04210,603Direct
Dec 30, 2025Common StockSSaleDisposed−100$40.36−$4,03610,503Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Dec 29, 2025Common StockMOption exerciseDisposed−72,400$0.00$074,243Direct
Dec 30, 2025Common StockMOption exerciseDisposed−100$0.00$074,143Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)